Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Anti-cancer natural products isolated from chinese medicinal herbs
2011 Standout
Cancer statistics, 2017
2017 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Cancer Statistics, 2021
2021 Standout
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial
2003
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Clinical translation of angiogenesis inhibitors
2002 Standout
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease
2003
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
2012 Standout
Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms
2019 Standout
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies
1995
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Therapeutic apheresis in neurological disorders
2000
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
2002
Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001
2002
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Bcr–Abl variants: biological and clinical aspects
2002
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
2015
A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer
2005
Multiple Myeloma
2004
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier
2001
Cellular signaling by fibroblast growth factor receptors
2005 Standout
Vascular disorders of the liver # †
2008 Standout
Neurologic Complications of Plasma Cell Disorders
2004
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
2005
Acute Mesenteric Ischemia
2004 Standout
Fusion of the BCR and the fibroblast growth factor receptor‐1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: The first fusion gene involving BCR but not ABL
2001
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
2002
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
2009
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
2006
NF-κB and IKK as therapeutic targets in cancer
2006 Standout
Treatment of hairy-cell leukemia
1990
Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier
2002
AGA technical review on intestinal ischemia
2000 Standout
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
2001
Risk assessment in haematopoietic stem cell transplantation: Viral status
2007
Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up
2010
Monoclonal Gammopathy of Undetermined Significance
2005
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Thalidomide
2004
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
2004
Drug Insight: thalidomide as a treatment for multiple myeloma
2005
Mesenteric Venous Thrombosis
2013
An Update on Monoclonal Gammopathy and Neuropathy
2011
Natural compounds for cancer treatment and prevention
2009 Standout
Cloning, expression, and cellular localization of the oncogenic 58-kDa inhibitor of the RNA-activated human and mouse protein kinase
1996
FcRn: the neonatal Fc receptor comes of age
2007 Standout
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
2001
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
2015
Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus‐like autoantibody synthesis
2006
Mitoxantrone
1996
The blood-brain barrier: Bottleneck in brain drug development
2004 Standout
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma
2002
Effects ofBCR-ABLAntisense Oligonucleotides (AS-ODN) on Human Chronic Myeloid Leukemic Cells: AS-ODN as Effective Purging Agents
1995
Neuroinflammation: the devil is in the details
2016 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
β-Arrestin2 mediates the initiation and progression of myeloid leukemia
2012 StandoutNobel
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
2001
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
2002
Recent major improvement in long-term survival of younger patients with multiple myeloma
2007
Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo
2006
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
2001
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Low-dose of thalidomide in the treatment of refractory myeloma.
2000
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
2005
Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.
2000
Treatment for IgG and IgA paraproteinaemic neuropathy
2015
XBP-1 Regulates a Subset of Endoplasmic Reticulum Resident Chaperone Genes in the Unfolded Protein Response
2003 Standout
A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).
2003
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Thalidomide in multiple myeloma
2005
Growth Factors and Cancer
1991 StandoutScience
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
2008
Multiple Myeloma
2011 Standout
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup
2004
Works of Claes Malm being referenced
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
2011
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
2000
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens
2006
Recombinant interferon‐alpha‐2b treatment of hairy‐cell leukaemia: Experience with a low‐dose schedule
1988
Poor survival in t(8;21)(q22;q22)‐associated acute myeloid leukaemia with leukocytosis
1997
Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies
1993
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia
1991
Intensive treatment in order to minimize the ph‐positive clone in chronic myelogenic leukemia
1993
Trisomy 13 as a primary chromosome aberration in acute leukemia
1991
Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV‐I) following allogeneic bone marrow transplantation for HTLV‐I positive adult T‐cell leukaemia
1994
Ig-secreting cells pass the blood-brain barrier: studies on κ and λ light chain secreting cells in plasma cell dyscrasia
1992
Cytogenetic polyclonality in hematologic malignancies
1999 Nobel
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
2013
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
1993